← Browse by Condition
Medical Condition
melanoma
Total Trials
20
Recruiting Now
20
Trial Phases
Phase 1, Phase 1, Phase 2
Melanoma has been at the forefront of precision oncology and immunotherapy for over a decade. The discovery that approximately 50% of cutaneous melanomas harbor BRAF V600E/K mutations led to the development of BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib), while the success of ipilimumab and nivolumab established immunotherapy as a curative-intent treatment for advanced disease, with long-term survival exceeding 20% at 10 years in some trials.
Current trials investigate anti-PD-1/LAG-3 combinations (relatlimab/nivolumab, already approved), triple checkpoint blockade, personalized neoantigen vaccines combined with anti-PD-1, tumor-infiltrating lymphocyte (TIL) therapy (lifileucel, FDA approved), and BRAF/MEK inhibitor combinations with immunotherapy for BRAF-mutated disease. Adjuvant trials aim to prevent recurrence in resected high-risk Stage III disease.
BRAF mutation status is required for enrollment in targeted therapy trials. Uveal, mucosal, and acral melanoma subtypes have distinct biology and are studied separately from cutaneous melanoma.
Frequently Asked Questions — melanoma Clinical Trials
How many clinical trials are currently recruiting for melanoma?
ClinicalMetric currently tracks 20 actively recruiting clinical trials for melanoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 20. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for melanoma?
melanoma research spans Phase 1 (9 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a melanoma clinical trial?
Eligibility criteria for melanoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 9
Phase 2 4
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07124000
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
AstraZeneca
NCT07224425 Phase 1
Recruiting
Enrollment
69 pts
Location
United States, Belgi...
Sponsor
Boehringer Ingelheim
NCT07475572 Phase 1
Recruiting
Enrollment
120 pts
Location
Ukraine
Sponsor
Alvotech Swiss AG
NCT03685890 Phase 1, Phase 2
Recruiting
Enrollment
74 pts
Location
Netherlands, Sweden
Sponsor
Vastra Gotaland Region
NCT06708663 Phase 1, Phase 2
Recruiting
Enrollment
124 pts
Location
China
Sponsor
Hangzhou Hanx Biopharmaceutica...
NCT05673681
Recruiting
Enrollment
7,000 pts
Location
Spain
Sponsor
Fundación Academia Española de...
NCT04913285 Phase 1
Recruiting
Enrollment
400 pts
Location
United States, Austr...
Sponsor
Pierre Fabre Medicament
NCT07042243
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
University of Florida
NCT04038619 Phase 1
Recruiting
Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07403630
Recruiting
Enrollment
300 pts
Location
Italy
Sponsor
Azienda Ospedaliero-Universita...
NCT07225036
Recruiting
Enrollment
21 pts
Location
United States
Sponsor
Jordan Kharofa
NCT02332668 Phase 1, Phase 2
Recruiting
Enrollment
370 pts
Location
United States, Brazi...
Sponsor
Merck Sharp & Dohme LLC
NCT05373823
Recruiting
Enrollment
385 pts
Location
United States
Sponsor
Rutgers, The State University ...
NCT05746897 Phase 1
Recruiting
Enrollment
38 pts
Location
United States
Sponsor
Hefei TG ImmunoPharma Co., Ltd...
NCT06861023
Recruiting
Enrollment
10 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
NCT03941756
Recruiting
Enrollment
252 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05983237 Phase 1, Phase 2
Recruiting
Enrollment
50 pts
Location
China
Sponsor
Jun Guo
NCT06627595
Recruiting
Enrollment
160 pts
Location
France
Sponsor
University Hospital, Montpelli...
NCT07883954
Recruiting
Enrollment
2,000 pts
Location
Belgium, Germany, Sp...
Sponsor
Mitra Bio
NCT06536257
Recruiting
Enrollment
1,000 pts
Location
Australia
Sponsor
Melanoma Institute Australia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology